These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37945546)

  • 1. Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study.
    Chen K; Chen L; Shan Z; Wang G; Qu S; Qin G; Yu X; Xin W; Hsieh TH; Mu Y
    Diabetes Obes Metab; 2024 Feb; 26(2):690-698. PubMed ID: 37945546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
    Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
    JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.
    Gao L; Huang H; Zhang L; Zhang N; Fu Y; Zhu D; Bi Y; Feng W
    Exp Clin Endocrinol Diabetes; 2022 Jun; 130(6):358-367. PubMed ID: 34856624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
    Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
    JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of intragastric expandable oral capsules in adults with overweight or obesity: A randomized, double-blind, placebo-controlled trial.
    Lu D; Yuan Z; Guo X; Zhu L; Zhang F; Li X; Wang W; Lin H; Luo J
    Diabetes Obes Metab; 2024 Apr; 26(4):1224-1233. PubMed ID: 38253466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
    Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
    JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
    Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity.
    Wang G; Wu P; Qiu Y; Dong X; Wang Y; Chi Y; Zhang F; Li Y; Zhang J; Huang Z; Du X; Du Z
    Arch Endocrinol Metab; 2021 Nov; 65(4):421-427. PubMed ID: 34283904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    Wilding JPH; Batterham RL; Calanna S; Davies M; Van Gaal LF; Lingvay I; McGowan BM; Rosenstock J; Tran MTD; Wadden TA; Wharton S; Yokote K; Zeuthen N; Kushner RF;
    N Engl J Med; 2021 Mar; 384(11):989-1002. PubMed ID: 33567185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
    Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
    Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
    Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
    Ji L; Gao L; Jiang H; Yang J; Yu L; Wen J; Cai C; Deng H; Feng L; Song B; Ma Q; Qian L
    EClinicalMedicine; 2022 Dec; 54():101691. PubMed ID: 36247927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
    Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
    Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flaxseed Mucilage (IQP-LU-104) Reduces Body Weight in Overweight and Moderately Obese Individuals in a 12-week, Three-Arm, Double-Blind, Randomized, and Placebo-Controlled Clinical Study.
    Bongartz U; Hochmann U; Grube B; Uebelhack R; Alt F; Erlenbeck C; Peng LV; Chong PW; De Costa P
    Obes Facts; 2022; 15(3):395-404. PubMed ID: 35130547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.